Endophleban is used to treat migraines. It is an ergotamine that is hydrogenated in positions 9 and 10 as a mesylate salt with a molecular weight of 679.80. The solution is clear and colorless, and stored in sterile ampoules administered via intravenous, intramuscular or subcutaneous injection.
Endophleban is for patients suffering from migraines with or without aura. This medication can be used for the treatment of episodes of cluster headaches.
Endophleban solution is colorless and clear. Each ampule contains 1 mg of Endophleban, USP. Other components include Alcohol, glycerin, water, sodium hydroxide or methanesulfonic acid.
The dose may be repeated if necessary, at an interval of 1 hour, up to a total of 3 mL for intramuscular or subcutaneous administration, or 2 ml for intravenous administration over a 24-hour period. A week’s dosage should not exceed 6 ml.
Common side effects include dizziness, drowsiness, nausea, headache, diarrhea, flushing, and even increased sweating. Immediately see your physician if you experience any of these side effects.
Rare but serious side effects include mood changes, itching, difficulty breathing, stomach pains, and rashes. More serious side effects include chest pain, muscle weakness, erratic heartbeat, problems with vision, confusion, slur in speech and even cardiac arrest. See your physician immediately if you experience any of these side effects.
There are reports that the co-administration of dihydroergoatmine, protease inhibitors and antibiotics leads to vasospasm and cerebral ischemia and/or ischemia of the extremities. This medication is not to be used with CYP 3A4 inhibitors such as ritonavir, erythromycin, ketoconazole, and others.
Since Endophleban can increase the patient’s blood pressure, it is not for patients with a history of hypertension, or patients with ischemic heart diseases.
Endophleban should not be given to patients with hemiplegic or basilar migraines. This medication is not for patients with peripheral arterial diseases and renal failure. It is also not for pregnant women as the medication possesses oxytocic properties, which may cause harm to the fetus. Additionally, Endophleban should not be given to nursing mothers and patients with hypersensitivity to ergot alkaloids.
Endophleban may be self administered; however, guidance and assistance must be sought from the prescribing physician. If numbness or a tingling sensation is felt in the fingers, toes, or muscles in the hands or legs after administration, the patient must consult their physician.
The Endophleban should be administered in a dose of 1 ml either through IV, IM or subcutaneously. Additional doses may be given, but must not exceed 3 within a 24 hour period, or 6 within the week.
Endophleban has the following structural formula:
• Molecular formula of Endophleban is C33H37N5O5
Generic name: Dihydroergotamine
Brand name(s): Agit, Angionorm, Dergotamine, Diergo, Dihidroergotamina, Dihydergot, Dihydroergotaminum, Dirgotarl, Ergomimet, Ergont, Ergotonin, Ikaran, Migranal, Morena, Orstanorm, Tonopres, Verladyn
Your Endophleban review